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Abstract
Background Pityriasis rubra pilaris (PRP) is a rare chronic inﬂammatory dermatosis with multifactorial aetiology. It is
known that particular caspase recruitment domain family member 14 (CARD14) gene mutations are associated with
familial PRP and certain forms of psoriasis. Additionally, few data are available about the role of CARD14 gene variants
in sporadic PRP. The clinical picture is variable for the different types of PRP, therefore choosing the adequate treatment
is often difﬁcult, furthermore there are no speciﬁc guidelines for therapy.
Objective Our aim was to survey the efﬁcacy of the applied therapies and to screen the CARD14 gene variants in our
PRP patients.
Methods In this retrospective study, patients diagnosed with PRP between 2006 and 2016 at our clinic were involved.
Besides the follow-up study of the treatments, the genetic analysis of CARD14 gene was performed.
Results We analysed 19 patients, among whom 17 were diagnosed with type I, one with type III, and one with type V
PRP. The majority of the patients were successfully treated with acitretin in combination with systemic corticosteroids,
and the remaining patients were treated with other systemic therapies with diverse effects. The genetic screening of
CARD14 gene revealed two previously described mutations (rs114688446, rs117918077) and six polymorphisms
(rs28674001, rs2066964, rs34367357, rs11653893, rs11652075, rs2289541). Ten of 19 patients carried different
CARD14 genetic variants either alone or in combination.
Conclusion Based on our experience, we propose that acitretin and an initial combination of short-term systemic corti-
costeroid therapy could be a successful treatment option for PRP. Although we identiﬁed several CARD14 variants in
almost half of our cases, we did not ﬁnd a correlation between the therapeutic response and the genetic background.
Our data support the previous observation that CARD14 genetic variants are not speciﬁc to PRP, although they may indi-
cate chronic inﬂammation.
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Introduction
Pityriasis rubra pilaris (PRP) is a rare chronic inflammatory
papulosquamous dermatosis of uncertain aetiology manifested
by palmoplantar keratoderma, follicular hyperkeratotic papules
and reddish-orange scaly plaques often with characteristic
islands of sparing. The skin symptoms may often progressively
worsen and become erythrodermic; nevertheless, a spontaneous
remission may occur a few years after the onset of the disease.
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According to Griffiths, PRP is classified into five forms: classic
adult type, atypical adult type, classic juvenile type, circum-
scribed juvenile type and atypical juvenile type. Recently,
HIV-associated form, as a sixth category has been added to this
classification (Table 1).1,2
Most of PRP cases are sporadic. However, approximately 5%
of the cases are familial and show autosomal dominant inheri-
tance.3 Previously, Fuchs-Telem and co-workers have revealed
that familial PRP develops as a consequence of the activation of
the NF-jB signalling pathway due to rare mutations of the cas-
pase recruitment domain family member 14 (CARD14) gene.4
Moreover, CARD14 gene variants are implicated in sporadic
PRP as well.5–7 In addition, CARD14 single nucleotide polymor-
phisms (SNP) and gain-of-function mutations have been
reported in psoriasis.8 Besides the genetic similarities, these ery-
thematosquamous diseases share common phenotypical features
that make the diagnosis often difficult.9
Since the treatment options in PRP are limited and there are
no specific guidelines for the therapy, it is important to investi-
gate the associated genetic background of PRP patients to estab-
lish genotype–phenotype correlations, which may lead to better
therapeutic approaches. Here, we describe the efficacy of the
applied therapy in our PRP patients, and the identified genetic
variants of the CARD14 gene.
Materials and methods
Patients
In this retrospective, non-controlled study, we analysed PRP
patients at the University of Szeged Department of Dermatology
and Allergology between 2006 and 2016. The definitive PRP
diagnosis was based on the clinical and histopathologic informa-
tion. Nineteen patients were diagnosed with PRP, and the classi-
fication of PRP was defined according to Griffiths (Table 1).
The patients’ demographic and clinical data were collected, and
the therapeutic outcome was followed. This study was approved
by the Human Investigation Review Board of the University of
Szeged and carried out in compliance with the Declaration of
Helsinki. All patients provided written informed consent.
Genetic investigations
Genetic analysis of the CARD14 gene was performed using diag-
nostic formalin-fixed paraffin-embedded skin biopsies of
patients that were available in our histological archive (n = 12)
or blood samples of the patients (n = 7). The paraffin-
embedded tissues were deparaffinized and genomic DNA was
isolated using the BioRobot EZ1 DSP Workstation (QIAGEN;
Hilden, Germany). The coding region of the CARD14 gene and
the flanking introns were amplified applying primer sequences
displayed on UCSC Genome Browser (http://genome.ucsc.edu/)
and DNA sequencing was performed on the amplification prod-
ucts. Direct sequencing was performed on an ABI 3100 sequen-
cer and compared with the wild-type gene at the Ensembl
Genome Browser (https://www.ensembl.org/). The indicated
minor allele frequencies (MAFs) are according to Caucasian
databases.
Results
Clinical background
During the 10-year follow-up, 19 PRP cases were diagnosed,
whose clinical characteristics, demographic data and genetic
variants are summarized in Table 2. The mean age of the
patients at the time of their diagnosis was 55.16 (range, 8–73)
years. Based on the literature, the disease occurs equally in both
sexes,10 nonetheless, we diagnosed 13 male and 6 female
patients.
Seventeen patients had type I PRP; one patient had type III
PRP. One patient was diagnosed with type V PRP; her family
members (father, sisters, daughter and grandchild) had similar
skin lesions and were diagnosed with psoriasis, moreover in her
childhood this type V PRP patient was misdiagnosed with psori-
asis. Similarly, Patient 15 with type I PRP was also misdiagnosed
with psoriasis ten years prior to our PRP diagnosis. In these
cases, both the clinical features as well as the histopathology
indicated PRP.
The above mentioned observations are in line with the
described difficulties in the differential diagnosis between psoria-
sis and PRP.11 In 13 patients, the disease started with erythro-
derma.
Genetic screening of the CARD14 gene
All of the 19 patients were screened for CARD14 gene variants.
Nine of the patients showed wild-type CARD14, while in 10
patients several CARD14 genetic variants were identified alone
or in combination, these variants are listed in Table 3. The
genetic sequence analysis identified two CARD14 mutations,
both of them missense mutations and had already been
described previously (rs114688446, rs117918077), marked with
Table 1 Classiﬁcation of PRP, according to Grifﬁths
Type Age at
onset
Ratio
(%)
Clinical manifestation
I Adult 55 Red-orange plaques, follicular papules,
erythroderma with ‘napples claires’,
diffuse palmoplantar keratoderma, nail
involvement
II Adult 5 Ichtiosiform scaling on legs, eczematous
dermatitis, nonscarring alopecia
III 5–10 years 10 Similar to type I
IV 3–10 years 25 Well demarcated areas with follicular
hyperkeratosis on elbows and knees
V 0–4 years 5 Follicular hyperkeratosis, Familial PRP
VI Variable <5 Similar to type I, in HIV positive patients
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an asterisk in Table 2. The rs114688446 and rs117918077 muta-
tions of the CARD14 gene were described previously not only in
PRP, but in psoriasis as well. The association of the rare variant
rs114688446 with psoriasis vulgaris and generalized pustular
psoriasis was previously described in American cohorts with
European ancestry and this rare variant is assumed as a potential
modifier for disease onset.8,12 Although there is a significant
association between these mutations and papulosquamous
diseases, their in vitro functional studies did not reveal any effect
on NF-jB activation.6,8 The in silico predicted effect of these two
mutations on protein function is considered benign (Ensembl,
NCBI/refSNP, VarSome, SIFT, PolyPhen2). In our previous
functional study, we identified one of these mutations
(rs117918077) and additional 3 CARD14 variants (rs28674001,
Table 2 Clinical/demographic data of the patients, therapeutic outcomes and detected genetic variants
Patient No./
sex/type
based on
Grifﬁths
Age at
onset
Family
history
Erythroderma CARD14 variants Therapy Therapy
response
Disease
duration
(months)
Additional
information
1/female/I 62 NA Yes neg SS+acitretin Symptom-free 3
2./male/I 61 neg Yes neg SS+acitretin Symptom-free 3
3./male/I 32 neg No neg SS+acitretin Symptom-free 6
4./male/I 73 neg Yes rs114688446†
rs11652075
SS+acitretin Symptom-free 9
5./male/I 60 NA Yes rs2066964 SS+acitretin Symptom-free 19
6./male/I 56 neg Yes neg SS+acitretin+
PUVA
Symptom-free 42
7./male/I 73 neg Yes Rs34367357 rs28674001
rs11653893 rs11652075
SS+acitretin Symptom-free 16
(ongoing)
Later relapses,
maintenance
therapy is
necessary
8./male/I 68 neg yes rs2066964 rs28674001
rs11653893 rs11652075
SS+acitretin Symptom-free 19
(ongoing)
Later relapses,
maintenance
therapy is
necessary
9./male/I 67 NA yes rs2066964 Vitamin A,
SS+azathiorin,
SS+acitretin
Symptom-free 10 later CTCL, than
he died
10./male/I 69 neg yes rs2066964 SS+PUVA,
SS+MTX
Symptom-free 4
11./male/I 66 neg no rs2289541 rs2066964
rs28674001 rs11653893
rs11652075
Acitretin Symptom-free 7 later BP
12./female/I 55 NA no neg Acitretin Symptom-free 22 frequent relapses
13./female/III 8 neg no neg Vitamin A Almost
symptom-free
5
14./female/V 61 psoriasis yes rs117918077†
rs2066964 rs28674001
rs11652075
Acitretin,
ustekinumab
Improving
symptoms
17
(ongoing)
15./male/I 60 neg yes neg PUVA, acitretin,
MTX
Almost always
symptomatic
132
(ongoing)
His previous
diagnosis was
psoriasis for
10 years
16./female/I 46 psoriasis no neg vitamin A, acitretin,
extracorporeal
photochemotherapy
Almost always
symptomatic
144
(ongoing)
17./male/I 48 neg yes rs2066964 311 nm UVB Symptomatic 2 Alcohol addiction,
noncompliance,
relapse, died
18./male/I 40 neg no neg Acitretin NA NA Noncompliance
19./female/I 43 neg no rs28674001 rs11653893
rs11652075
Topical steroid NA NA Noncompliance
†Minor allele frequency <0.01.
SS, systemic corticosteroid; PUVA, psoralen+ultraviolet A; MTX, methotrexate.
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rs2066964, rs11653893) in a type V PRP patient, who demon-
strated increased NF-jB activation in skin biopsies, isolated ker-
atinocytes and peripheral blood mononuclear cells (PBMCs).
The higher inflammatory state cannot be explained exclusively
by the CARD14 variants, but the cumulative effect of these vari-
ants may contribute to the increased NF-jB activity.13
Besides the two mutations, further 6 CARD14 polymorphisms
were identified as follows: 4 missense (rs2066964, rs34367357,
rs11652075, rs2289541) and 2 splice site variants (rs28674001,
rs11653893). All of these SNPs have been described previously in
psoriasis and/or in PRP in a number of cohorts.6–8,14 The
rs2066964 variant was identified with high frequency in sporadic
PRP patients.6,7 Eskin-Schwartz and co-workers investigated a
family with CARD14-related psoriasis, and they found the
rs2066964, rs11652075 and rs34367357 polymorphisms in
severely affected individuals which suggest a possible association
of these SNPs with the severity of the disease.14 The common
rs11652075 polymorphism has been associated with the develop-
ment of psoriasis8,15 and it was described in sporadic PRP
patients as well.6,7 As far as the function of these SNPs based on
in silico analysis, all are considered benign (Ensembl, VarSome).
Moreover, a previous study revealed that the rs2066964 poly-
morphism has no significant influence on NF-jB activation
in vitro.16 The in vitro function of the other 5 SNPs was not
investigated yet.
Therapy and outcome
Spontaneous remission was not observed in our patients. In 6
patients, the therapy is still ongoing, 11 patients were treated
successfully without reoccurrence of the symptoms during the
follow-up. Two patients died of different causes irrespective of
their PRP. The patients’ treatment and disease outcomes are
shown in Table 2. We determined the disease duration as the
time period from the beginning of the therapy to the asymp-
tomatic or nearly asymptomatic stage.
All patients received topical skin care therapy combined with
systemic therapy; the topical treatment included corticosteroids,
keratolytics and emollients. Based on our clinical experience and
the available data, it is very likely that systemic therapy is neces-
sary in most cases.
Eight patients received a combination of systemic corticos-
teroids and acitretin as first-line therapy. Five of them had a
complete recovery within 8  6.6 months and they have
remained in remission (follow-up 64  58.1 months). (Patient
6 who was initially treated with corticosteroid and acitretin can-
not be compared to the similarly treated other group, because
his corticosteroid therapy was abruptly discontinued). At the
start of the steroid therapy – when patients displayed extensive
inflammatory signs or erythroderma – they received systemic
corticosteroids in a relatively low dose (0.5 mg/kg pred-
nisolone). The steroid dose was gradually reduced according to
their symptoms. At the same time, acitretin was started usually
at a 10 mg/day dose, which later was increased to 20–25 mg, if
necessary. Acitretin was usually continued until patients
achieved complete remission (10.4  6.8 months). Of the eight
patients treated with this combined therapy, two relapsed when
acitretin was discontinued after 16 and 19 months, and we rein-
troduced their previous therapy. Currently, both of them are
given a maintenance dose of 5–10 mg prednisolone/day and 10–
20 mg acitretin/day, and they are symptom-free. It is worth
mentioning that these two patients had the highest number of
genetic variants in this group.
Patient 9 first received different kinds of therapies before the
combination of systemic corticosteroid and acitretin was intro-
duced, and he became symptom-free. Following a six-month
symptom-free period, he developed cutaneous T cell lymphoma
(CTCL).
The other 10 patients were treated with several systemic thera-
pies, such as acitretin in monotherapy, high dose vitamin A,
methotrexate, azathioprine, PUVA, extracorporeal photoche-
motherapy and ustekinumab. Patient 11 was given acitretin
monotherapy and responded well and became almost symptom-
free in 7 months when, however, he developed bullous pem-
phigoid. Regarding his new disease, we supplemented his previous
treatment with systemic steroid therapy. Our only familial PRP
patient has been on ustekinumab therapy for 1.5 years, her symp-
toms improved but she is not symptom-free. In the remaining
eight patients, the various other therapies did not seem to help,
since two are either symptomatic or have frequent relapses. We
have two patients in this group with no information on the course
of their disease.
Conclusion
Due to the rare disease prevalence and the wide range of clinical
manifestations, the diagnosis of PRP can be very difficult in cer-
tain cases: clinical findings can overlap with other skin diseases,
therefore PRP is often misdiagnosed, mainly as psoriasis.9,17
However, in most cases histopathology can help to distinguish
these two erythematosquamous skin disorders from each other.
Typical histological features of PRP include psoriasiform hyper-
plasia, follicular hyperkeratosis, perivascular lymphocytic infil-
trate, and intact or thickened stratum granulosum. In contrast,
Table 3 Detected CARD14 variants of the PRP patients
Variant ID Variant cDNS Variant prot Function MAF Exon
rs114688446 c.599G/A p.Ser200Asn Missense 0.01 4
rs28674001 c.676-6G/A – Splice site 0.34 4–5
rs2066964 c.1641G/C p.Arg547Ser Missense 0.37 14
rs34367357 c.1753G/A p.Val585Ile Missense 0.08 15
rs117918077 c.2044C/T p.Arg682Trp Missense 0.01 17
rs11653893 c.2399-4A>G – Splice site 0.36 17–18
rs11652075 c.2458C/T p.Arg820Trp Missense 0.35 20
rs2289541 c.2648G/A p.Arg883His Missense 0.02 21
MAF, minor allele frequency (Reported MAF at www.ensembl.org).
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in psoriasis there are characteristic hypogranulosis and the pres-
ence of Munro microabscesses. However, the histologic spec-
trum of both PRP and psoriasis is varied and in atypical PRP,
cases can overlap with psoriasis.11,18 In addition, since there are
no specific or uniformly effective therapy guidelines available in
PRP, finding the successful treatment is also often challenging.
Hence, the detailed understanding of the PRP pathogenesis, the
associated genetic background and establishing genotype–phe-
notype association are essential, and may contribute to the
investigation of new therapeutic approaches in PRP.
Recent studies demonstrated that familial PRP has been
associated with CARD14 mutations, which are also identified
in familial psoriasis.19 CARD14 protein is higher expressed in
the skin than in any other organs.20 CARD14 is a known acti-
vator of NF-jB signalling, which is involved in inflammatory
disorders due to the regulation of proliferation, differentiation
and apoptosis.21 NF-jB may play a crucial role in the patho-
genesis of psoriasis and is also implicated in PRP.22 Takeichi
and co-workers suggested that CARD14 mutations as common
genetic features may give an explanation to the clinicopatho-
logical similarities between PRP and psoriasis vulgaris.23
Moreover, Craiglow and co-workers recommended a new term
CARD14-associated papulosquamous eruption to characterize
this spectrum of disease. They found that the clinical symp-
toms of the patients in this group are very similar indepen-
dently of their diagnosis being either psoriasis or PRP.9 In our
familial PRP patient with CARD14 mutation, the overlap
between psoriasis and PRP was strongly suspected. However,
the other patient with CARD14 mutation presented typical
reddish-orange scaly plaques and islands of sparing character-
istic of PRP.
Previous studies showed that the occurrence of CARD14
mutations in sporadic PRP is very low (0–12.5%).6,7,24 In agree-
ment with these data, we demonstrated CARD14 mutation in
5.3% of our sporadic PRP cases. In this study, we showed
already reported SNPs in 38.9% of our 18 sporadic PRP patients,
all of which have been previously described in PRP and in psori-
asis.6,8,12,14,15 In vitro functional studies of rs114688446 and
rs117918077 mutations and the rs2066964 SNP demonstrated
no functional effects of these variants on NF-jB activity.6,8 The
other 5 CARD14 gene variants have not been studied in vitro so
far. The in vitro functional studies were performed separately
with the variants, therefore, we cannot exclude the possible
involvement of the combined presence of different variants in
one patient.13
Unfortunately, there is not enough data to establish a gener-
ally accepted therapeutic guideline for PRP. Although an impor-
tant part of the management is the topical therapy, most PRP
patients need systemic therapy. Some reports recommended
ultraviolet-B phototherapy for juvenile type IV PRP.25 One of
our adult patients received UVB phototherapy, however, he sub-
sequently relapsed. Other studies suggested that topical retinoids
or corticosteroids may be sufficient in some cases, mainly in
localized forms of the disease.26,27
Due to the rarity of PRP, only case reports and case series are
available regarding the therapeutic options in the literature.
Most reported reviews consider oral retinoids as first-line ther-
apy.10,28 Some studies indicated that PUVA and re-PUVA (oral
retinoid and phototherapy) are presumably good alternatives.
There are also some data indicating good clinical response to
methotrexate. Moreover, cyclosporine, extracorporeal pho-
tochemotherapy and fumaric acid may also be used efficiently.10
These medications are particularly applied in refractory cases
with diverse effects. Recently, biological therapies, such as TNF-
alpha blocking agents, IL-23 and IL-17 inhibitors may also
represent therapeutic options.29,30 Ustekinumab acting on the
NF-jB pathway may be effective in cases of PRP with a gain-
of-function mutation in CARD14.5
Systemic corticosteroids are considered to be ineffective and
not used in PRP and psoriasis in general. It is well documented
that if steroid is used as a monotherapy, the withdrawal may
trigger the exacerbation of the disease, as in psoriasis.31,32 How-
ever, the use of systemic corticosteroids in adequate dosage and
in combination with other systemic treatment is beneficial in
most cases of acute or erythrodermic psoriasis.33 Erythroderma
can develop as a complication of PRP, however, the reported
incidence in the literature shows high variability.10 According to
some authors, erythroderma is a very frequent complication of
PRP.34,35 Piamphongsan and co-workers identified only 4 chil-
dren and 10 adults with exfoliative erythroderma among 168
investigated patients.36 PRP progressed to exfoliative erythro-
derma in 68.4% of our patients, mainly at the beginning of the
disease. The majority of our PRP patients with erythroderma
received combined therapy with systemic corticosteroid and aci-
tretin. Among our patients, this combination from the begin-
ning of the therapy seemed to be the most useful treatment. It is
important to note that patients did not present any side effects
during this treatment. Steroids are known to inhibit the NF-jB
pathway and if this pathway is important in PRP the beneficial
steroid effect can be explained. It is also obvious that steroid
therapy itself is not sufficient for treatment, suggesting that
excess inflammation is only part of the pathomechanism. The
good therapeutic effect of acitretin indicates that besides the
abnormal immune regulation, keratinocyte proliferation and
differentiation processes are also contributing to the pathomech-
anism.
The CARD14 gene mutations and SNPs may partially explain
the chronic inflammation in PRP; however, in accordance with
the literature, they are not specific to PRP, they only indicate
chronic inflammatory disorders, and that is why they can be
detected in some psoriasis cases. However, the reported rare and
common SNPs of CARD14 in both diseases could explain the
clinical and histopathological similarities between cases of PRP
and psoriasis.
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